SkipperH.E., SchabelF.M., WilcoxW.S.: Experimental evaluation of potential anticancer agents, XIII. On the criteria and kinetics associated with “curability” of experimental leukemia.Cancer Chemother Rep, 35: 1–111, 1964.
BaguleyB.C., HoldawayK.M., ThomsenL.L., ZhuangL., ZwiL.J.: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism.Eur J Cancer, 27: 482–487, 1991.
5.
WaniM.C., TaylorH.L., WallM.E., CaggonP., McPhailA.T.: Plant antitumor agents, VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.J Am Chem Soc, 93: 2325–2327, 1971.
6.
RowinskyE.K., DonehowerR.C.: Taxol: twenty years later, the story unfolds.J Natl Cancer Inst, 83: 1778–1781, 1991.
NogalesE., WolfS.G., KhanI.A., LuduenaR.F., DowningK.H.: Structure of tubulin at 6.5 A and location of the taxol-binding site.Nature, 375: 424–427, 1995.
10.
ParnessJ., HorwitzS.B.: Taxol binds to polymerized tubulin in vitro.J Cell Biol, 91: 479–487, 1981.
11.
SchiffP.B., FantJ., HorwitzS.B.: Promotion of microtubule assembly in vitro by taxol.Nature, 277: 665–667, 1979.
JordanM.A., TosoR.J., ThrowerD., WilsonL.: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.PNAS USA, 90: 9552–9556, 1993.
14.
MilrossC., HunterN., MasonK., PetersL., MilasL.: Dependency of antitumor effect of Taxol on its ability to induce mitotic arrest and apoptosis.Proc AACR, 36: 2094, 1995.
15.
WangT.H., WangH.S., SoongY.K.: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.Cancer, 88: 2619–2628, 2000.
16.
TorresK., HorwitzS.B.: Mechanism of taxol-induced cell death are concentration dependent.Cancer Res, 58: 3620–3626, 1998.
17.
MoosP.J., FitzpatrickF.A.: Taxane-mediated gene induction is independent of microtubule stabilization: induction of trascription regulators and enzymes that modulate inflammation and apoptosis.Proc Natl Acad Sci USA, 95: 3896–3901, 1998.
18.
CabralF., TrimbleE., ReedE., SarosyG.: Future directions with taxane therapy.Hematology/Oncology Clinics of North America, 13: 21–41, 1999.
19.
KingT.C., AkerlyW., FanA.C., MooreT., MangrayS., HsiuC.M., SafranH.: p53 mutations do not predict response to paclitaxel in metastatic non small cell lung carcinoma, Cancer, 89: 769–773, 2000.
20.
TakahashiM., KigawaJ., MinagawaY., ItamochiH., ShimadaM., KamazawaS., SatoS., AkeshimaR., TerakawaN.: Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.Eur J Cancer, 36: 1863–1868, 2000.
21.
KavallarisM., PouhaS., FlemmingC., NorrisM.D., HaberM., Lutze-mannL.: Induction of p53 by DNA damage represses the expression of microtubule proteins in human neuroblastoma cells.Proceedings AACR, abst 2227, 2001.
22.
BlagosklonnyM.V., BishopP.C., RobeyR., FojoT., BatesS.E.: Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells.Cancer Res, 60: 3425–3428, 2000.
23.
ZhangC.C., YangJ.M., Bash-BabulaJ., WhiteE., MurphyM., LevineA.J., HaitW.N.: DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxAanes through p53-dependent repression of microtubule -associated protein 4.Cancer Res, 59: 3663–3670, 1999
24.
GokulS., McGuckinA.G., HallA.G., CalvertH., LunecJ.: Comparison of p53 mutation screening by direct sequencing and a thermomodulated HPLC system.Proceedings AACR, abst 1186, 2001.
25.
MarkmanM.: Weekly paclitaxel in the management of ovarian cancer.Semin Oncol, 27(suppl 7): 37–40, 2000.
26.
HaldarS., BasuA., CroceC.M.: Bcl-2 is the guardian of the genome integrity.Cancer Res, 57: 229–233, 1997.
27.
De FeudisP., VignatiS., RossiC., MincioniT., GiavazziR., D'IncalciM., BrogginiM.: Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.Neoplasia, 2: 202–207, 2000.
28.
StrobelT., KraeftS.K., ChenL.B., CannistraS.A.: BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.Cancer Res, 58: 4776–4781, 1998.
29.
MilasL., HunterN.R., KurdogluB., MasonK.A., MeynR.E., StephensL.G., PetersL.J.: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.Cancer Chemother Pharmacol, 35: 297–303, 1995.
30.
MilrossC.G., MasonK.A., HunterN.R., ChungW., PetersL.J., MilasL.: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.J Natl Cancer Inst, 88: 1308–1314, 1996.
31.
SymmansW.F., VolmM.D., ShapiroR.L., PerkinsA.B., KimA.Y., DemariaS., YeeH.T., McMullenH., OratzR., KleinP., FormentiS.C., MuggiaF.: Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.Clin Cancer Res, 6: 4610–4617, 2000.
32.
WatsonJ.M., KingstonD.G.I., ChordiaM.D., ChaudharyA.G., RinehartC.A., HaskillJ.S.: Identification of the structural region of Taxol that may be responsible for cytokine gene induction and cytotoxicity in human ovarian cancer cells.Cancer Chemother Pharmacol, 41: 391–397, 1998.
33.
AuJ.L., LiD., GanY., GaoX., JohnsonA.L., JohnstonJ., Mil-lenbaughN.J., JangS.H., KuhH.J., ChenC.T., WientjesM.G.: Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.Cancer Res, 58: 2141–2148, 1998.
34.
GardnerS.N.: A mechanistic predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.Cancer Res, 60: 1417–1425, 2000.
35.
LevasseurL.M., SlocumH.K., RustumY.M., GrecoW.R.: Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.Cancer Res, 58: 5749–5761, 1998.
36.
BelottiD., VerganiV., DrudisT., BorsottiP., PitelliM.R., VialeG., GiavazziR., TarabolettiG.: The microtubule-affec-ting drug paclitaxel has antiangiogenic activity.Clin Cancer Res, 2: 1843–1849, 1996.
37.
KlauberN., ParangiS., HamelE., FlynnE., D'AmatoR.J.: Inhibition of angiogenesis in vivo by the microtubule inhibitors 2-methoxyestradiol and taxol.Cancer Res, 57: 81–86, 1997.
38.
LauD.H., XueL., YoungL.J., BurkeP.A., CheungA.T.: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.Cancer Biother Ra-diopharm, 14: 31–37, 1999.
39.
SeidmanA.D., HudisC.A., AlbanelJ., TongW., TeplerI., CurrieV., MoynahanM.E., TheodoulouM., GollubM., Ba-selgaJ., NortonL.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.J Clin Oncol, 16: 3353–3361, 1998.
LofflerT.M., FreundW., LipkeJ., HausamenT.U.: Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.Semin Oncol, 23(suppl 16): 32–34, 1996.
42.
GottesmanM.M., HrycynaC.A., SchoenleinP.V., GermannU.A., PastanI.: Genetic analysis of the multidrug transporter.Ann Rev Gen, 29: 607–649, 1995.
43.
KavallarisM., KuD.Y.S., BurkhartC.A., ReglD.L., NorrisM.D., HaberM., HorwitzS.B.: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific betatubulin isotypes.J Clin Inves, 100: 1282–12931997.
44.
KuoD.Y.S., MallickS., ShenH.J., DeVictoriaC., JonesJ., FieldsA.L., GoldbergG.L., RunowiczC.D., HorwitzS.B.: Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry.Clin Cancer Res, 2: 1981–1992, 1996.
45.
GiannakakouP., SackettD.L., KangY.K., ZhanZ., ButersJ.T., FojoT., PoruchynskyM.S.: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.J Biol Chem, 272: 17118–17125, 1997.
46.
OlmstedJ.B., BorisyG.G.: Characterization of microtubule assembly in porcine brain extracts by viscometry.Biochemistry, 12: 4282–4289, 1993.
47.
WangX.M., PeloquinJ.G., ZhaiY., BulinskiJ.C., BorisyG.G.: Removal of MAP4 from microtubules in vivo produces no discernible phenotype at the cellular level.J Cell Biol, 132: 349–358, 1996.
48.
SullivanK.F.: Structure and utilization of tubulin isotypes.Ann Rev Cell Biology, 4: 687–716, 1988.
49.
PanvichianR., OrthK., DayM.L., DayK.C., PilatM.J., PientaK.J.: Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance.Cancer Res, 58: 4667–4672, 1998.
50.
NortonL.: Adjuvant breast cancer therapy: current status and future strategies-growth kinetics and the improved drug therapy of breast cancer.Semin Oncol, 26(suppl 3): 1–4, 1999.
